{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abiraterone+Oral+Tablet&page=2", "query": { "intervention": "Abiraterone Oral Tablet", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 74, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abiraterone+Oral+Tablet&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abiraterone+Oral+Tablet&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T12:04:21.597Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05276492", "title": "Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer", "Prostate Adenocarcinoma", "Prostate Neoplasm", "Prostate Cancer Metastatic" ], "interventions": [ { "name": "Abiraterone Oral Tablet", "type": "DRUG" }, { "name": "Prednisone tablet", "type": "DRUG" }, { "name": "Drug Dairy/Log", "type": "OTHER" }, { "name": "Low-fat meal", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2023-01-24", "completion_date": "2024-11-16", "has_results": false, "last_update_posted_date": "2025-10-03", "last_synced_at": "2026-10-04T12:04:21.597Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05276492" }, { "nct_id": "NCT03261336", "title": "Oral Calcitriol With Ketoconazole in CRPC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Calcitriol, Ketoconazole, Hydrocortisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Donald Trump, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2017-01-06", "completion_date": "2018-02-28", "has_results": true, "last_update_posted_date": "2021-02-08", "last_synced_at": "2026-10-04T12:04:21.597Z", "location_count": 1, "location_summary": "Fairfax, Virginia", "locations": [ { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03261336" }, { "nct_id": "NCT00924469", "title": "A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Abiraterone", "type": "DRUG" }, { "name": "Leuprolide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 58, "start_date": "2009-11", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2013-04-17", "last_synced_at": "2026-10-04T12:04:21.597Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Houston, Texas • Seattle, Washington + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" }, { "city": "Wenatchee", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00924469" }, { "nct_id": "NCT03568656", "title": "Study to Evaluate CCS1477 in Advanced Tumours", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Castration-Resistant Prostate Cancer", "Metastatic Breast Cancer", "Non-small Cell Lung Cancer", "Advanced Solid Tumors" ], "interventions": [ { "name": "CCS1477", "type": "DRUG" }, { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CellCentric Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 219, "start_date": "2018-07-23", "completion_date": "2025-07-06", "has_results": true, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-04T12:04:21.597Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Philadelphia, Pennsylvania", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03568656" }, { "nct_id": "NCT03834519", "title": "Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 793, "start_date": "2019-05-02", "completion_date": "2024-01-27", "has_results": true, "last_update_posted_date": "2025-05-18", "last_synced_at": "2026-10-04T12:04:21.597Z", "location_count": 29, "location_summary": "Fullerton, California • Los Angeles, California • Washington D.C., District of Columbia + 24 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Quincy", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03834519" }, { "nct_id": "NCT06691984", "title": "Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Xaluritamig", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Cabazitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 707, "start_date": "2024-12-09", "completion_date": "2029-07-30", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-10-04T12:04:21.597Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Duarte, California • Fullerton, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06691984" }, { "nct_id": "NCT02649790", "title": "Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed/Refractory Multiple Myeloma (RRMM)", "Metastatic Colorectal Cancer (mCRC)", "Metastatic Castration-Resistant Prostate Cancer (mCRPC)", "Higher-Risk Myelodysplastic Syndrome (HR-MDS)", "Acute Myeloid Leukemia (AML)", "Newly Diagnosed Intermediate/High-Risk MDS" ], "interventions": [ { "name": "KPT-8602", "type": "DRUG" }, { "name": "ASTX727", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 277, "start_date": "2016-01", "completion_date": "2024-12-23", "has_results": false, "last_update_posted_date": "2025-03-19", "last_synced_at": "2026-10-04T12:04:21.597Z", "location_count": 26, "location_summary": "Los Angeles, California • Pasadena, California • Aurora, Colorado + 23 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Littleton", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02649790" }, { "nct_id": "NCT00485303", "title": "An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostatic Neoplasms", "Prostate Cancer" ], "interventions": [ { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cougar Biotechnology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 58, "start_date": "2007-06", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2013-07-02", "last_synced_at": "2026-10-04T12:04:21.597Z", "location_count": 12, "location_summary": "Los Angeles, California • San Francisco, California • Baltimore, Maryland + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00485303" }, { "nct_id": "NCT01897389", "title": "A Study to Assess the Relative Bioavailability of 4 New Abiraterone Acetate Tablet Formulations With Respect to the Current Commercial Abiraterone Acetate Tablet Under Fasted Conditions in Healthy Male Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Treatment A", "type": "DRUG" }, { "name": "Treatment B", "type": "DRUG" }, { "name": "Treatment C", "type": "DRUG" }, { "name": "Treatment D", "type": "DRUG" }, { "name": "Treatment E", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 32, "start_date": "2013-07", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2014-12-02", "last_synced_at": "2026-10-04T12:04:21.597Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01897389" }, { "nct_id": "NCT01314118", "title": "IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer", "Prostatic Neoplasm" ], "interventions": [ { "name": "abiraterone acetate in combination with prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Biotech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "MALE", "summary": "18 Years to 99 Years · Male only" }, "enrollment_count": 131, "start_date": "2011-05-04", "completion_date": "2024-12-02", "has_results": true, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-10-04T12:04:21.597Z", "location_count": 45, "location_summary": "Homewood, Alabama • Huntsville, Alabama • Tucson, Arizona + 42 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01314118" } ] }